Drug Development for Malaria

Pravin Kendrekar studied chemistry at Swami Ramanand Teerth Marathwada University (India) and completed his Ph.D. in Organic Chemistry at Nagoya University of Technology (Japan). After post-doctoral work at Ben Gurion University (Israel) and the University of the Free State (South Africa), he joined the Central University of Technology at Bloemfontein (South Africa) in 2017, where he is currently a group leader in the Unit for Drug Discovery Research. He also holds a position as business development director with T&T Pharma Care in Thane (India). The primary focus of his work is in antimalarial therapy.

• INTRODUCTIONPast, Present and Future Drug Development for Malaria CHALLENGES AND OPPORTUNITIES IN MALARIA THERAPYScientific Challenges and Treatment Opportunities in the Face of Shifting Malaria EpidemiologyRecent Advances in Malaria Vaccine DevelopmentEmerging Formulation Technologies against Malaria ResurgenceTargeted Drug Delivery for Malarial TherapyThe Imminent Threat of Antimalarial Drug ResistanceCurrent Therapies and New Drug Targets for the Future Drug Development of Drug Resistant MalariaBringing an Antimalarial Drug to MarketDRUG DEVELOPMENTAssays for Antimalarial Drug DiscoveryRole of Computer Aided Drug Design (CADD) in Designing Anti-malarial AgentsAminoacyl-tRNA Synthetases as Malarial Drug Targets: A Structural Biology PerspectiveRole of Natural Compounds for Prevention and Treatment of MalariaNatural Products as a source for Antimalarial Drug Development ProcessAn Overview into the Anti-plasmodial South African Medicinal PlantsThe Antimalarial Potential of MushroomsCASE STUDIESDiscovery and Trends of 8-Aminoquinoline and 4-Aminoquinoline Classes of AntimalarialsDiscovery and Development of ArtemisininSynthesis, Characterization and Antimicrobial Drug Efficacy of the Oxaborole DerivativesDiscovery and Development of beta (β)-Carboline Derivatives as Anti-malarial Agents